DRonabinol Treatment of OSA
ConditionObstructive Sleep Apnea
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
AgeUp to 65
SponsorVA Office of Research and Development
About this trial
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
Eligibility criteria
Qualifiers
None
Disqualifiers
Positive Airway Pressure (PAP) treatment of OSA: use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report
History of upper airway surgery for OSA (except adenotonsillectomy)
Central or mixed apneas >25% of respiratory events on diagnostic polysomnography
Trial design
Treatments tested in this trial
- Dronabinol
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
VA Office of Research and Development
Lead sponsor
University of Illinois at Chicago
Collaborator
Source ClinicalTrials.gov